CONMED Corporation (CNMD)

Return on total capital

Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 118,079 171,907 181,271 200,326 198,014 162,607 142,918 120,604 69,322 63,270 -51,701 -41,956 -3,645 -2,309 110,951 108,589 95,985 99,694 52,652 45,653
Long-term debt US$ in thousands
Total stockholders’ equity US$ in thousands 1,008,260 1,002,870 977,636 962,681 932,896 881,832 854,664 834,222 796,205 780,194 752,453 745,545 716,337 672,968 789,546 785,435 755,683 744,499 725,570 709,038
Return on total capital 11.71% 17.14% 18.54% 20.81% 21.23% 18.44% 16.72% 14.46% 8.71% 8.11% -6.87% -5.63% -0.51% -0.34% 14.05% 13.83% 12.70% 13.39% 7.26% 6.44%

September 30, 2025 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $118,079K ÷ ($—K + $1,008,260K)
= 11.71%


Peer comparison

Sep 30, 2025

Company name
Symbol
Return on total capital
CONMED Corporation
CNMD
11.71%
Abbott Laboratories
ABT
17.01%
Stryker Corporation
SYK
20.07%